- Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population
[作者：Sun, T; Lee, GSM; Oh, WK; Pomerantz, M; Yang, M; Xie, WL; Freedman, ML; Kantoff, PW,期刊：Clinical Cancer Research, 页码：5244-5251 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: The tumor suppressor p53 plays a crucial role in maintaining genomic stability and tumor prevention. Mdm2, Mdm4, and Hausp are all critical regulators of the p53 protein. Despite the importance of the p53 pathwa...
- Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma
[作者：Simon, M; Hosking, FJ; Marie, Y; Gousias, K; Boisselier, B; Carpentier, C; Schramm, J; Mokhtari, K; Hoang-Xuan, K; Idbaih, A; Delattre, JY; Lathrop, M; Robertson, LB; Houlston, RS; Sanson, M,期刊：Clinical Cancer Research, 页码：5252-5259 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: Genome-wide association studies have recently identified single-nucleotide polymorphisms (SNP) in five loci at 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A/CDKN2B), 20q13.33 ...
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
[作者：Carr, LL; Mankoff, DA; Goulart, BH; Eaton, KD; Capell, PT; Kell, EM; Bauman, JE; Martins, RG,期刊：Clinical Cancer Research, 页码：5260-5268 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)-avid, iodine-refractory well-differentiated thyroi...
- Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study
[作者：Keizman, D; Zahurak, M; Sinibaldi, V; Carducci, M; Denmeade, S; Drake, C; Pili, R; Antonarakis, ES; Hudock, S; Eisenberger, M,期刊：Clinical Cancer Research, 页码：5269-5276 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer. Experimental Design: Sixty men with non-castrate, nonmetast...
- A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
[作者：Kimball, KJ; Preuss, MA; Barnes, MN; Wang, MH; Siegal, GP; Wan, W; Kuo, HC; Saddekni, S; Stockard, CR; Grizzle, WE; Harris, RD; Aurigemma, R; Curiel, DT; Alvarez, RD,期刊：Clinical Cancer Research, 页码：5277-5287 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: To determine the maximum tolerated dose (MTD), toxicity spectrum, clinical activity, and biological effects of the tropism-modified, infectivity-enhanced conditionally replicative adenovirus (CRAd), Ad5-.24-Arg-...
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor alpha, in Epithelial Ovarian Cancer: a Phase I Study
[作者：Konner, JA; Bell-McGuinn, KM; Sabbatini, P; Hensley, ML; Tew, WP; Pandit-Taskar, N; Els, NV; Phillips, MD; Schweizer, C; Weil, SC; Larson, SM; Old, LJ,期刊：Clinical Cancer Research, 页码：5288-5295 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: Folate receptor alpha expression is highly restricted in normal adult tissues but upregulated in a wide range of human cancer types, including epithelial ovarian cancer. Farletuzumab, a humanized monoclonal anti...
- Sequential Cytarabine and alpha-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
[作者：Rosenblat, TL; McDevitt, MR; Mulford, DA; Pandit-Taskar, N; Divgi, CR; Panageas, KS; Heaney, ML; Chanel, S; Morgenstern, A; Sgouros, G; Larson, SM; Scheinberg, DA; Jurcic, JG,期刊：Clinical Cancer Research, 页码：5303-5311 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML). To increase the potency of the antibody without the ...
- Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
[作者：Schmidt, H; Brown, J; Mouritzen, U; Selby, P; Fode, K; Svane, IM; Cook, GP; Mollerup, DH; Geertsen, PF,期刊：Clinical Cancer Research, 页码：5312-5319 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor ac...
- Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
[作者：Chambers, SK; Clouser, MC; Baker, AF; Roe, DJ; Cui, HY; Brewer, MA; Hatch, KD; Gordon, MS; Janicek, MF; Isaacs, JD; Gordon, AN; Nagle, RB; Wright, HM; Cohen, JL; Alberts, DS,期刊：Clinical Cancer Research, 页码：5320-5328 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also don...
- CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer
[作者：de Jong, MC; Pramana, J; van der Wal, JE; Lacko, M; Peutz-Kootstra, CJ; de Jong, JM; Takes, RP; Kaanders, JH; van der Laan, BF; Wachters, J; Jansen, JC; Rasch, CR; van Velthuysen, MLF; Grenman, R; Hoebers, FJ; Schuuring, E; van den Brekel, MW; Begg, AC,期刊：Clinical Cancer Research, 页码：5329-5338 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: To find molecular markers from expression profiling data to predict recurrence of laryngeal cancer after radiotherapy. Experimental Design: We generated gene expression data on pre-treatment biopsies from 52 lar...
- The IFNG (IFN-gamma) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia
[作者：Kim, DH; Kong, JH; Byeun, JY; Jung, CW; Xu, W; Liu, XD; Kamel-Reid, S; Kim, YK; Kim, HJ; Lipton, JH,期刊：Clinical Cancer Research, 页码：5339-5350 , 文章类型： Article，,卷期：2010年16-21]
- Purpose: The present study analyzed treatment outcomes of imatinib therapy by interindividual genetic variants in candidate biological pathways of chronic myeloid leukemia (CML) such as apoptosis, angiogenesis, IFN-gamma...
|